KR100514132B1 - Composition and kit for losing body weight - Google Patents
Composition and kit for losing body weight Download PDFInfo
- Publication number
- KR100514132B1 KR100514132B1 KR10-2003-0038371A KR20030038371A KR100514132B1 KR 100514132 B1 KR100514132 B1 KR 100514132B1 KR 20030038371 A KR20030038371 A KR 20030038371A KR 100514132 B1 KR100514132 B1 KR 100514132B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- weight loss
- herbal
- composition
- ephedra
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 91
- 230000037396 body weight Effects 0.000 title description 4
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims abstract description 71
- 230000004580 weight loss Effects 0.000 claims abstract description 65
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims abstract description 36
- 229960002179 ephedrine Drugs 0.000 claims abstract description 35
- 241000218671 Ephedra Species 0.000 claims abstract description 33
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 16
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 16
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 16
- 230000029087 digestion Effects 0.000 claims abstract description 16
- 229940010454 licorice Drugs 0.000 claims abstract description 16
- 241000202807 Glycyrrhiza Species 0.000 claims abstract description 15
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 13
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 13
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 13
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 13
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 13
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 13
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 13
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 13
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 13
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 13
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 12
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 12
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 12
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 10
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 9
- 235000017276 Salvia Nutrition 0.000 claims abstract description 8
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 7
- 230000007812 deficiency Effects 0.000 claims abstract description 7
- 230000002708 enhancing effect Effects 0.000 claims abstract description 7
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 4
- 240000007164 Salvia officinalis Species 0.000 claims abstract 3
- 244000241838 Lycium barbarum Species 0.000 claims abstract 2
- 239000006187 pill Substances 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 claims description 3
- 235000002789 Panax ginseng Nutrition 0.000 claims description 2
- 239000012676 herbal extract Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 57
- 230000001079 digestive effect Effects 0.000 abstract description 12
- 230000032683 aging Effects 0.000 abstract description 9
- 230000037394 skin elasticity Effects 0.000 abstract description 9
- 238000004260 weight control Methods 0.000 abstract description 5
- 230000037303 wrinkles Effects 0.000 abstract description 5
- 230000033001 locomotion Effects 0.000 abstract description 3
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 239000004576 sand Substances 0.000 abstract 1
- 230000006870 function Effects 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 208000008589 Obesity Diseases 0.000 description 11
- 235000020824 obesity Nutrition 0.000 description 11
- 241001092040 Crataegus Species 0.000 description 10
- 230000009471 action Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 244000241872 Lycium chinense Species 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 7
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 7
- 235000005493 rutin Nutrition 0.000 description 7
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 7
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 7
- 229960004555 rutoside Drugs 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 206010033307 Overweight Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 241001072909 Salvia Species 0.000 description 5
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 201000006549 dyspepsia Diseases 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 235000019154 vitamin C Nutrition 0.000 description 5
- 239000011718 vitamin C Substances 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- IKGXIBQEEMLURG-UHFFFAOYSA-N Rutin Chemical compound OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-UHFFFAOYSA-N 0.000 description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 235000017159 Crataegus pinnatifida Nutrition 0.000 description 3
- 241000657480 Crataegus pinnatifida Species 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 240000004371 Panax ginseng Species 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000004872 arterial blood pressure Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000013872 defecation Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 238000005265 energy consumption Methods 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- -1 flavonoid compounds Chemical class 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- TYPSVDGIQAOBAD-DZGCQCFKSA-N Atractylone Chemical compound C([C@]1(C)C2)CCC(=C)[C@@H]1CC1=C2OC=C1C TYPSVDGIQAOBAD-DZGCQCFKSA-N 0.000 description 2
- 206010012239 Delusion Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 240000000249 Morus alba Species 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- 244000293610 Morus bombycis Species 0.000 description 2
- 235000006721 Morus bombycis Nutrition 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 241000612118 Samolus valerandi Species 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 231100000868 delusion Toxicity 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 208000024798 heartburn Diseases 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 235000021374 legumes Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000020879 medical diet Nutrition 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 2
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- XXHSUYNZCSBPBG-GZIDCZEMSA-N quercetin 3-beta-gentiotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC[C@@H]2[C@H]([C@H](O)[C@@H](O)[C@H](OC=3C(C4=C(O)C=C(O)C=C4OC=3C=3C=C(O)C(O)=CC=3)=O)O2)O)O1 XXHSUYNZCSBPBG-GZIDCZEMSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- XDUXBBDRILEIEZ-LJQANCHMSA-N (6s)-6-(hydroxymethyl)-1,6-dimethyl-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCC[C@](C)(CO)C3=CC=C2C2=C1C(C)=CO2 XDUXBBDRILEIEZ-LJQANCHMSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- HXWZQRICWSADMH-SEHXZECUSA-N 20-hydroxyecdysone Natural products CC(C)(C)CC[C@@H](O)[C@@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C HXWZQRICWSADMH-SEHXZECUSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 241000509537 Alisma canaliculatum Species 0.000 description 1
- 235000013291 Alisma plantago aquatica Nutrition 0.000 description 1
- 240000004615 Alisma plantago-aquatica Species 0.000 description 1
- WXHUQVMHWUQNTG-UHFFFAOYSA-N Alisol E 24-acetate Natural products CC12CCC(=O)C(C)(C)C1CCC1(C)C2C(O)CC2=C(C(CC(O)C(OC(C)=O)C(C)(C)O)C)CCC21C WXHUQVMHWUQNTG-UHFFFAOYSA-N 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- FBMORZZOJSDNRQ-GLQYFDAESA-N Atractylenolide III Chemical compound C=C([C@@H]1C2)CCC[C@]1(C)C[C@@]1(O)C2=C(C)C(=O)O1 FBMORZZOJSDNRQ-GLQYFDAESA-N 0.000 description 1
- 241000132011 Atractylodes lancea Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 244000201986 Cassia tora Species 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- YJHVMPKSUPGGPZ-UHFFFAOYSA-N Dihydro-beta-eudesmol Natural products C1CC(C(C)(C)O)CC2C(C)CCCC21C YJHVMPKSUPGGPZ-UHFFFAOYSA-N 0.000 description 1
- DCEFCUHVANGEOE-UHFFFAOYSA-N Ecdysterone Natural products CC(CC(C)(C)O)C(O)C(C)(O)C1CCC2(O)C3=CC(=O)C4CC(O)C(O)CC4(C)C3CCC12C DCEFCUHVANGEOE-UHFFFAOYSA-N 0.000 description 1
- LLKXNMNOHBQSJW-UHFFFAOYSA-N Elemol Natural products CCC(=C)C1CC(C=CC1(C)C)C(C)(C)O LLKXNMNOHBQSJW-UHFFFAOYSA-N 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000723281 Ephedra equisetina Species 0.000 description 1
- 241001465251 Ephedra sinica Species 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- UGNZSMZSJYOGNX-UHFFFAOYSA-N Isoviocristine Natural products O=C1C=C(C)C(=O)C2=CC3=CC(OC)=CC(O)=C3C(O)=C21 UGNZSMZSJYOGNX-UHFFFAOYSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- FURUXTVZLHCCNA-UHFFFAOYSA-N Liquiritigenin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-UHFFFAOYSA-N 0.000 description 1
- 241001106041 Lycium Species 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 241000867418 Morion Species 0.000 description 1
- 241000218213 Morus <angiosperm> Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 244000046101 Sophora japonica Species 0.000 description 1
- 235000010586 Sophora japonica Nutrition 0.000 description 1
- NTFQHAKUNDRGJR-UHFFFAOYSA-N Sophoradiol Natural products CC1(C)CC(O)C2(C)CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1 NTFQHAKUNDRGJR-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 1
- XDUXBBDRILEIEZ-UHFFFAOYSA-N Tanshinone IIB Natural products O=C1C(=O)C2=C3CCCC(C)(CO)C3=CC=C2C2=C1C(C)=CO2 XDUXBBDRILEIEZ-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- WXHUQVMHWUQNTG-JSWHPQHOSA-N [(3r,4s,6r)-2,4-dihydroxy-6-[(5r,8s,9s,10s,11s,14r)-11-hydroxy-4,4,8,10,14-pentamethyl-3-oxo-1,2,5,6,7,9,11,12,15,16-decahydrocyclopenta[a]phenanthren-17-yl]-2-methylheptan-3-yl] acetate Chemical compound C([C@@]12C)CC(=O)C(C)(C)[C@@H]1CC[C@@]1(C)[C@H]2[C@@H](O)CC2=C([C@@H](C[C@H](O)[C@@H](OC(C)=O)C(C)(C)O)C)CC[C@@]21C WXHUQVMHWUQNTG-JSWHPQHOSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229930188824 alisol Natural products 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- IPZIYGAXCZTOMH-UHFFFAOYSA-N alpha-eudesmol Natural products CC1=CCCC2CCC(CC12)C(C)(C)O IPZIYGAXCZTOMH-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- WLXGUTUUWXVZNM-UHFFFAOYSA-N anthraglycoside A Natural products C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1OC1OC(CO)C(O)C(O)C1O WLXGUTUUWXVZNM-UHFFFAOYSA-N 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- TYPSVDGIQAOBAD-HIFRSBDPSA-N atractylon Natural products Cc1coc2C[C@]3(C)CCCC(=C)[C@H]3Cc12 TYPSVDGIQAOBAD-HIFRSBDPSA-N 0.000 description 1
- TYPSVDGIQAOBAD-UHFFFAOYSA-N atractylone Natural products C1C2(C)CCCC(=C)C2CC2=C1OC=C2C TYPSVDGIQAOBAD-UHFFFAOYSA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- XFSVWZZZIUIYHP-UHFFFAOYSA-N beta-Eudesmol Natural products CC(C)(O)C1CCC2CCCC(=C)C2C1 XFSVWZZZIUIYHP-UHFFFAOYSA-N 0.000 description 1
- NKDFYOWSKOHCCO-UHFFFAOYSA-N beta-ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(C)(O)C)CCC33O)C)C3=CC(=O)C21 NKDFYOWSKOHCCO-UHFFFAOYSA-N 0.000 description 1
- BOPIMTNSYWYZOC-VNHYZAJKSA-N beta-eudesmol Chemical compound C1CCC(=C)[C@@H]2C[C@H](C(C)(O)C)CC[C@]21C BOPIMTNSYWYZOC-VNHYZAJKSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 description 1
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 1
- GFJIQNADMLPFOW-UHFFFAOYSA-N cis-Elemol Natural products CC(=C)C1CC(C(C)(C)O)CCC1(C)C=C GFJIQNADMLPFOW-UHFFFAOYSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- GFJIQNADMLPFOW-VNHYZAJKSA-N elemol Chemical compound CC(=C)[C@@H]1C[C@H](C(C)(C)O)CC[C@@]1(C)C=C GFJIQNADMLPFOW-VNHYZAJKSA-N 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- WWULHQLTPGKDAM-UHFFFAOYSA-N gamma-eudesmol Natural products CC(C)C1CC(O)C2(C)CCCC(=C2C1)C WWULHQLTPGKDAM-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- NQYPTLKGQJDGTI-FCVRJVSHSA-N hyperoside Natural products OC[C@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3[C@H]2O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@H]1O NQYPTLKGQJDGTI-FCVRJVSHSA-N 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 1
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- FURUXTVZLHCCNA-AWEZNQCLSA-N liquiritigenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-AWEZNQCLSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960002221 methylephedrine Drugs 0.000 description 1
- 208000001022 morbid obesity Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000003880 negative regulation of appetite Effects 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NCAIGTHBQTXTLR-UHFFFAOYSA-N phentermine hydrochloride Chemical compound [Cl-].CC(C)([NH3+])CC1=CC=CC=C1 NCAIGTHBQTXTLR-UHFFFAOYSA-N 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 1
- XXHSUYNZCSBPBG-UHFFFAOYSA-N quercetin-3-gentotrioside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC2C(C(O)C(O)C(OC=3C(C4=C(O)C=C(O)C=C4OC=3C=3C=C(O)C(O)=CC=3)=O)O2)O)O1 XXHSUYNZCSBPBG-UHFFFAOYSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- ZEGUWBQDYDXBNS-FVFJQADASA-N sophoradiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)[C@H](O)CC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C ZEGUWBQDYDXBNS-FVFJQADASA-N 0.000 description 1
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02K—DYNAMO-ELECTRIC MACHINES
- H02K16/00—Machines with more than one rotor or stator
- H02K16/02—Machines with one stator and two or more rotors
-
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02K—DYNAMO-ELECTRIC MACHINES
- H02K15/00—Processes or apparatus specially adapted for manufacturing, assembling, maintaining or repairing of dynamo-electric machines
- H02K15/02—Processes or apparatus specially adapted for manufacturing, assembling, maintaining or repairing of dynamo-electric machines of stator or rotor bodies
- H02K15/03—Processes or apparatus specially adapted for manufacturing, assembling, maintaining or repairing of dynamo-electric machines of stator or rotor bodies having permanent magnets
-
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02K—DYNAMO-ELECTRIC MACHINES
- H02K21/00—Synchronous motors having permanent magnets; Synchronous generators having permanent magnets
- H02K21/12—Synchronous motors having permanent magnets; Synchronous generators having permanent magnets with stationary armatures and rotating magnets
- H02K21/14—Synchronous motors having permanent magnets; Synchronous generators having permanent magnets with stationary armatures and rotating magnets with magnets rotating within the armatures
-
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02K—DYNAMO-ELECTRIC MACHINES
- H02K21/00—Synchronous motors having permanent magnets; Synchronous generators having permanent magnets
- H02K21/12—Synchronous motors having permanent magnets; Synchronous generators having permanent magnets with stationary armatures and rotating magnets
- H02K21/22—Synchronous motors having permanent magnets; Synchronous generators having permanent magnets with stationary armatures and rotating magnets with magnets rotating around the armatures, e.g. flywheel magnetos
Landscapes
- Engineering & Computer Science (AREA)
- Power Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
본 발명은 체중 감소용 생약 조성물 및 그를 포함하는 키트에 관한 것으로서, 본 발명에 의한 체중 감소용 생약 조성물은, 체중 감소 기능의 마황, 소화 기능 증진용 생약 혼합물, 항산화 기능의 생약 혼합물, 오미자 및 감초를 포함하며, 상기 소화 기능 증진용 생약 혼합물은 창출, 산사, 택사 및 결명자로 구성되며, 상기 항산화 기능의 생약 혼합물은, 상엽, 괴화, 단삼 및 구기자로 구성되며, 상기 마황은 에페드린의 성인 기준 1일 단위 용량이 0.22 내지 0.44mg이 되는 함량으로 함유되며, 상기 창출은 15 내지 19중량%, 상기 산사, 택사 및 구기자는 각각 9 내지 13중량%, 괴화, 상엽, 결명자 및 단삼은 각각 7 내지 11중량%, 오미자 및 감초를 각각 2 내지 6중량%의 양으로 함유된 것을 특징으로 한다.The present invention relates to a herbal composition for weight loss and a kit comprising the same, wherein the herbal composition for weight loss according to the present invention includes ephedra of weight loss function, herbal mixture for enhancing digestion, herbal mixture for antioxidant function, schisandra chinensis and licorice It includes, the herbal mixture for enhancing digestive function is composed of creation, hawthorn, taxa and deficiency, the herbal mixture of the antioxidant function, consists of the upper leaf, lump, Salvia and goji, the ephedra is the adult standard of ephedrine 1 It contains a daily unit dose of 0.22 to 0.44 mg, the creation is 15 to 19% by weight, the mountain sand, tack and wolfberry are 9 to 13% by weight, respectively, lumps, upper leaves, gyeoljak and dansam 7 to 11 It is characterized by containing 2% by weight to 6% by weight, Schisandra chinensis and Licorice.
본 발명에 의한 체중 감소용 생약 조성물 및 키트는 특정 농도의 마황을 함유함으로써 에페드린의 투여로 인한 부작용을 예방하면서도 충분한 체중감소효과를 나타내는 조성물을 제공할 수 있다. 이와 같은 체중 조절 효과와 더불어, 동양인 특유의 체질을 고려하여 소화를 증진시켜 주며 숙변을 제거하고 배변을 용이하게 하는 효과가 있다. 또한, 체중 감소에 따른 노화를 방지하여 피부 탄력을 강화시키고 주름을 감소시키는 효과가 있다. The herbal composition and kit for weight loss according to the present invention may provide a composition which exhibits a sufficient weight loss effect while preventing side effects due to the administration of ephedrine by containing ephedra at a certain concentration. In addition to the weight control effect, considering the peculiar constitution of Asians, it promotes digestion, removes stool, and facilitates bowel movement. In addition, there is an effect of preventing aging due to weight loss to strengthen skin elasticity and reduce wrinkles.
Description
본 발명은 체중 감소용 조성물에 관한 것이다. 더욱 상세하게는 본 발명은 마황을 함유하는 체중 감소용 조성물에 관한 것이다. The present invention relates to a composition for weight loss. More particularly, the present invention relates to a weight loss composition containing ephedra.
현대에 들어와서는 미국 등의 서양에서 뿐만이 아니라 한국을 포함하는 동양권에서도 비만이 만연하고 있다. 이는 서구식 식생활에 대한 선호도가 높아졌기 때문인 것으로 보인다. 이에 따라, 예전에는 서양에서나 볼 수 있었던 거대한 비만 체형이 동양에서도 흔히 관찰되고 있는 실정이다. 이와 같은 현상은 어린이들에게도 두드러져 나타나므로 비만이라는 문제는 21세기 내내 부각될 것이다. In modern times, obesity is rampant not only in the West, such as the United States, but also in the East, including Korea. This seems to be due to increased preference for Western diet. Accordingly, the obese body shape that was previously seen only in the West is often observed in the East. This is especially true for children, so the problem of obesity will be highlighted throughout the 21st century.
비만은 체내에 과량의 지방이 축적된 것으로 정의할 수 있다. 이러한 지방의 과다축적은 에너지 수용과다(예컨대, 과량의 음식물)나 또는 에너지 소비 감소에 의해 일어나는, 에너지 소비보다 에너지 수용이 많은 경우의 결과로서 일어날 수 있다. 비만은 경미(20-30% 체중과다), 중간(30-60% 체중과다) 또는 심각(60% 체중과다)한 상태로 분류될 수 있다. 비만증은 여러가지로 건강을 해칠 수 있다. 비만은 심장 및 폐기능을 모두 해칠 수 있으며, 내분비기능을 혼란시키고 정신적인 문제를 일으킬 수 있다. 고혈압, 손상된 글루코스 내성 및 비-인슐린 의존성 당뇨병 및 과콜레스테롤혈증들은 정상체중을 갖는 사람보다 체중과다인 사람에게 더욱 흔한 증상이다. 그러므로 비만은 예컨대 고혈압, 발작, 당뇨병 타입 Ⅱ, 어떠한 유형의 암, 담낭질환 및 허혈성 심장병과 같은 질환에 시달리는 사람의 이병률 및 사망률에 한 몫을 할 수가 있다. 중간 및 심각한 비만 케이스는 사망률을 증가시키는 것으로 알려져 있다. 결장 및 직장암은 종종 자궁내막 또는 담낭암에 걸린 비만의 남녀에서 흔히 볼 수 있는 질병이다. 또한, 체중과다의 증가는 거의 결국에는 정신적 및 사회적 문제를 일으키는 것으로 인식되고 있다.Obesity can be defined as the accumulation of excess fat in the body. This over-accumulation of fat can occur as a result of more energy reception than energy consumption, caused by excessive energy consumption (eg, excess food) or reduced energy consumption. Obesity can be classified as mild (20-30% overweight), moderate (30-60% overweight), or severe (60% overweight). Obesity can harm your health in many ways. Obesity can damage both heart and lung function, disrupt endocrine function and cause mental problems. Hypertension, impaired glucose tolerance and non-insulin dependent diabetes mellitus and hypercholesterolemia are more common symptoms in overweight people than in normal weight. Obesity can therefore contribute to the morbidity and mortality of people suffering from diseases such as hypertension, seizures, diabetes type II, certain types of cancer, gallbladder disease and ischemic heart disease. Moderate and severe obesity cases are known to increase mortality. Colon and rectal cancer is a common disease in obese men and women who often have endometrial or gallbladder cancer. It is also recognized that an increase in overweight almost eventually causes mental and social problems.
상기와 같은 건강상의 이유 뿐만 아니라 비만은 특히 젊은 연령층에 있어서는 미용적 관점에서 관심이 크다. 건강학적 측면에서 비만이 아닌 극히 정상체중으로 나타나는 경우에도 자신이 뚱뚱하다고 생각하여 좀 더 날씬해지려는 욕구가 크다. 특히, 단순한 체중 감소의 관점이 아닌 아름다움 몸매를 지향하는(body line) 경향이 두드러졌다. 이러한 필요성으로 인해 비만 관련 산업이 점차 발달하여 거대한 시장이 형성되어 있다. 이에 따라, 의학적 검증을 거치지 않은 유사 의약, 또는 건강식품들의 수 또한 기하급수적으로 늘고 있다. 의료 유사 또는 의료직에 종사하지 않는 사람들의 비전문적 처치와 무리한 다이어트 시도로 인한 폐해가 끊임없이 보고되고 있다. 무리한 다이어트는 생명에도 지장을 초래할 수 있을 정도로 위험하다. 예컨대, 과다한 체액의 손실을 유발하는 다이어트나 지속적인 설사를 유발하는 성분의 복용, 성장호르몬의 주사 등은 생명에 지장을 초래할 수도 있다. In addition to the above health reasons, obesity is of particular interest in terms of beauty, especially in younger age groups. In terms of health, even if he appears to be extremely normal, not obese, he thinks he is fat and needs to become thinner. In particular, the trend toward body lines, rather than just weight loss, was prominent. Due to this necessity, obesity-related industries are gradually developed, forming a huge market. Accordingly, the number of similar drugs or health foods that have not undergone medical verification is also increasing exponentially. The damages caused by unprofessional treatment and unreasonable diet attempts by people who are not medically similar or not in the medical profession are constantly reported. Excessive diet is dangerous enough to cause life. For example, diet causing excessive body fluid loss, taking diuretic ingredients that cause persistent diarrhea, and injecting growth hormone may be harmful to life.
상기와 같은 문제를 내포하고 있는 비의료적 다이어트 방식은 겉으로 나타나는 수치상으로는 빠른 체중감량의 효과를 나타낼 수 있지만, 이에 비례하여 건강에는 악영향을 끼칠 수 있다. The non-medical diet method containing the above problems may show the effect of rapid weight loss on the surface, but in proportion to this may adversely affect health.
한편, 기존에 의학적으로 효능과 안정성이 입증된 적이 있는 일부 체중 감소용 약성분이 최근에는 치명적인 부작용을 유발하는 것으로 알려지면서, 그 사용에 대한 규제가 이루어지고 있다. 그 중에서 에페드린은 신경 및 심장 활동을 활성화시키는 자극물질로서 심장마비나 발작과 조울증, 망상, 불면증, 가슴 두근거림, 두통 등의 부작용을 유발할 수 있다는 보고가 나오고 있다. 그러나, 상기 부작용을 예방하기 위한 안전한 사용량 범위는 아직 알려진 바가 없었다. 특히, 어느 정도의 양을 사용해야만 상기 부작용 없이 안전하면서도 체중조절효과를 볼 수 있는지에 대해서는 구체적으로 알려진 바가 없었다. On the other hand, some weight loss drug ingredients that have been previously proved medically effective and stable have recently been known to cause fatal side effects, the use of the regulation is being made. Among them, ephedrine is an irritant that activates nerve and heart activity, and it has been reported that it may cause side effects such as heart attack, seizures and mood swings, delusions, insomnia, palpitations, and headaches. However, a safe dosage range for preventing the side effects is not known yet. In particular, it is not known in detail how much amount to use a safe and weight control effect without the side effects.
따라서, 비의료적인 다이어트 방식에 의한 폐해도 줄이면서, 부작용이 알려진 일부 체중감소용 성분의 안전한 유효량을 결정하는 데에 관심이 집중되고 있다. 한국인들을 포함하는 동양인들의 경우 체질적으로 서양인에 비해 소화가 잘 되지 않는 경향이 있다. 따라서, 동양인들의 체질에 맞게 처방하여 소화가 잘 되도록 해주는 것이 필요하다. 또한, 에페드린의 부작용을 없애면서도 체중조절의 효과를 유지할 수 있는 1일 투여범위를 밝히는 것이 절실히 요구되었다. 또한, 체중이 감소됨에 따라 피부 탄력이 감소되고 노화가 촉진되어 주름살이 늘어나는 문제점이 계속적으로 지적되어 왔다. 따라서, 체중을 감소시키면서도 노화를 예방할 수 있는 대책이 절실히 필요하였다. Therefore, attention has been focused on determining the safe and effective amount of some weight-reducing components for which side effects are known, while reducing macular degeneration by non-medical diet. Asians, including Koreans, tend to be less digestible than Westerners. Therefore, it is necessary to prescribe according to the constitution of Asians to be well digested. In addition, there is an urgent need to identify a daily dosage range that can maintain the effects of weight control while eliminating the side effects of ephedrine. In addition, as the weight is reduced, the problem that the skin elasticity is reduced and aging is accelerated to increase wrinkles have been pointed out. Therefore, there is an urgent need for measures to prevent aging while losing weight.
본 발명은 상기와 같은 문제점을 해결하기 위한 것으로서, 안전하면서도 체중감소효과를 나타내는 에페드린의 유효범위를 밝히는 것을 목적으로 한다. 또한, 동양인 특유의 체질을 고려하여 소화를 증진시켜 주며 체중 감소에 따른 노화를 방지할 수 있는 체중 감소용 조성물을 제공하는 것을 목적으로 한다. The present invention is to solve the above problems, it is an object of the present invention to reveal the effective range of ephedrine that shows a safe and weight loss effect. In addition, it is an object of the present invention to improve the digestion in consideration of the constitution unique to Asians and to provide a weight loss composition that can prevent aging due to weight loss.
상기와 같은 목적을 달성하기 위하여, 본 발명에 의한 체중 감소용 생약 조성물은, 체중 감소 기능의 마황, 소화 기능 증진용 생약 혼합물, 항산화 기능의 생약 혼합물, 오미자 및 감초를 포함하며, 상기 소화 기능 증진용 생약 혼합물은 창출, 산사, 택사 및 결명자로 구성되며, 상기 항산화 기능의 생약 혼합물은, 상엽, 괴화, 단삼 및 구기자로 구성되며, 상기 마황은 에페드린의 성인 기준 1일 단위 용량이 0.22 내지 0.44mg이 되는 함량으로 함유되며, 상기 창출은 15 내지 19중량%, 상기 산사, 택사 및 구기자는 각각 9 내지 13중량%, 괴화, 상엽, 결명자 및 단삼은 각각 7 내지 11중량%, 오미자 및 감초를 각각 2 내지 6중량%의 양으로 함유된 것을 특징으로 한다.In order to achieve the above object, the herbal composition for weight loss according to the present invention includes ephedra of weight loss function, herbal mixture for enhancing digestion function, herbal mixture for antioxidant function, Schisandra chinensis and licorice, Dragon Herbal Mixture consists of Creation, Sansa, Taxa, and Cassiae.The herbal mixture of antioxidant function is composed of upper leaves, lumps, Salvia, and Goji, and the ephedra has an adult daily dose of 0.22 to 0.44 mg of ephedrine. It is contained in such a content, the creation is 15 to 19% by weight, the hawthorn, tactile and goji berry each 9 to 13% by weight, lumps, upper leaves, gyeoljaja and sweet ginseng 7 to 11% by weight, respectively, Schisandra chinensis and licorice It is characterized by containing in an amount of 2 to 6% by weight.
삭제delete
삭제delete
삭제delete
삭제delete
한편, 본 발명에 의한 체중 감소용 생약 조성물은, 전체 조성물 중 유효성분을 기준으로 에페드린을 전체 조성물 중 0.016 내지 0.144중량%를 함유한 것을 특징으로 한다.On the other hand, the herbal composition for weight loss according to the present invention is characterized in that it contains 0.016 to 0.144% by weight of ephedrine in the total composition based on the active ingredient in the total composition.
삭제delete
상기 에페드린의 함유는 전체 조성물 중 유효성분을 기준으로 4 내지 8중량%의 마황을 함유함으로써 달성되는 것이 바람직하다. Containing the ephedrine is preferably achieved by containing 4 to 8% by weight of ephedra based on the active ingredient in the total composition.
상기 조성물은 생약 건조 혼합물 또는 상기 생약 건조 혼합물의 수용액 추출물인 액상 형태이다. The composition is in liquid form, which is an herbal dry mixture or an aqueous extract of the herbal dry mixture.
또한, 본 발명에 의한 체중 감소용 키트는 상기한 생약 건조 혼합물 또는 생약 건조 혼합물의 수용액 추출물인 액상 형태의 조성물을 포함한 것을 특징으로 한다.In addition, the kit for weight loss according to the present invention is characterized in that it comprises a composition of the liquid form which is an aqueous solution extract of the above-described herbal medicine dry mixture or herbal medicine dry mixture.
상기한 체중 감소용 키트는, 부형제를 제외한 유효성분을 기준으로 15 내지 19중량%의 창출, 각각 9 내지 13중량%의 산사, 택사 및 구기자, 각각 7 내지 11중량%의 괴화, 상엽, 결명자 및 단삼, 각각 2 내지 6중량%의 오미자 및 감초를 유효성분으로 함유한 요요현상 방지용 환제를 더 포함하는 것을 특징으로 한다.The weight loss kit is based on the active ingredients, except for excipients, 15 to 19% by weight, 9 to 13% by weight of hawthorn, talc and wolfberry, respectively, 7 to 11% by weight of lump, upper lobe, deficiency and Salvia is characterized in that it further comprises a yoyo phenomenon prevention pill containing 2 to 6% by weight of Schisandra chinensis and licorice as an active ingredient.
상기 요요현상 방지용 환제는 상기한 체중 감소용 생약 조성물을 모두 복용한 후에 복용하는 것을 특징으로 한다.The yo-yo phenomenon prevention pill is characterized in that after taking all of the herbal composition for weight loss.
이하, 본 발명에 의한 조성물 및 키트에 대해 더욱 상세히 설명한다. Hereinafter, the composition and kit according to the present invention will be described in more detail.
상기 마황은 전체 유효성분 중 4 내지 8중량%인 것이 바람직하며, 가장 바람직하게는 6중량%이다. 마황의 함량이 4중량% 미만인 경우에는 마황에 함유된 에페드린의 함량이 0.016중량% 미만이 되며, 이러한 에페드린의 함량으로는 충분한 체중 감량 효과를 달성하기가 어렵다. 한편, 마황의 함량이 8중량%를 초과하게 되면 그 마황에 함유된 에페드린의 함량이 0.144중량%를 초과하게 되는데, 이러한 에페드린의 함량은 고혈압 또는 심장질환과 같은 심각한 부작용을 초래할 수 있다. 이러한 관점에서 가장 바람직한 마황의 함량은 6중량%이다. The ephedra is preferably 4 to 8% by weight of the total active ingredient, most preferably 6% by weight. When the content of ephedra is less than 4% by weight, the content of ephedrine contained in ephedra is less than 0.016% by weight, and it is difficult to achieve a sufficient weight loss effect with this content of ephedrine. On the other hand, when the content of ephedra exceeds 8% by weight, the content of ephedrine contained in the ephedra exceeds 0.144% by weight, which may cause serious side effects such as hypertension or heart disease. The most preferable content of ephedra in this respect is 6% by weight.
한편, 창출은 전체 유효성분 중 15 내지 19중량% 함유하는 것이 바람직하며, 가장 바람직한 함량은 17중량%이다. 만일 창출의 함량이 15중량% 미만인 경우에는 소화기능 증진의 효과가 미미하며 19중량%를 초과하는 경우에는 다른 생약 성분과의 조화에 불균형을 초래한다. 이러한 관점에서 가장 바람직한 함량은 17중량%이다. On the other hand, the creation is preferably contained 15 to 19% by weight of the total active ingredient, the most preferable content is 17% by weight. If the content of generation is less than 15% by weight, the effect of enhancing digestion is insignificant, and if it exceeds 19% by weight, there is an imbalance in harmony with other herbal ingredients. The most preferable content in this respect is 17 weight%.
한편, 산사, 택사 및 구기자는 전체 유효성분 중 각각 9 내지 13중량% 함유하는 것이 바람직하다. 가장 바람직한 한량은 11중량%이다. 상기 함량이 9중량% 미만인 경우에는 각 성분의 효과가 미미하며 13중량%를 초과하는 경우에는 약제간의 조화 및 약제 안정성에 문제를 초래한다. 이러한 관점에서 가장 바람직한 함량은 11중량%이다. On the other hand, it is preferable to contain 9 to 13% by weight of the hawthorn, tack and wolfberry each of the total active ingredients. The most preferable amount is 11 weight%. When the content is less than 9% by weight, the effect of each component is insignificant, and when the content is more than 13% by weight causes problems in coordination between drugs and drug stability. The most preferable content in this respect is 11 weight%.
또한, 괴화, 상엽, 결명자 및 단삼은 전체 유효성분 중 각각 7 내지 11중량% 함유하는 것이 바람직하며, 가장 바람직한 함량은 9중량%이다. 만일 7중량% 미만이면 그 효과가 미미하며, 11중량%를 초과하면 약제간의 불균형이 초래된다. 이와 같은 관점에서 9중량% 함유하는 것이 가장 바람직하다.In addition, it is preferable to contain 7 to 11 weight% of total block of active ingredients, agglomerate, an upper lobe, a deficiency, and sweet ginseng, and the most preferable content is 9 weight%. If it is less than 7% by weight, the effect is insignificant, and if it exceeds 11% by weight, an imbalance between drugs is caused. It is most preferable to contain 9 weight% from such a viewpoint.
한편, 오미자 및 감초는 전체 유효성분 중 각각 2 내지 6중량% 함유하는 것이 바람직하며, 가장 바람직하게는 4중량%씩 함유하는 것이다. 만일 2중량% 미만인 경우에는 한약의 쓴맛을 감소시키고 독성을 감소시키는 효과가 미미하며, 6중량%를 초과하는 경우에는 다른 유효성분들의 기능을 저해할 수 있다. 이와 같은 관점에서 가장 바람직한 함량은 4중량%이다. On the other hand, Schisandra chinensis and licorice preferably contain 2 to 6% by weight, and most preferably 4% by weight of the total active ingredients. If less than 2% by weight, the effect of reducing the bitter taste and toxicity of the Chinese medicine is insignificant, and when it exceeds 6% by weight may inhibit the function of other active ingredients. In this respect, the most preferable content is 4% by weight.
본 발명에 있어서, 요요현상 방지용 환제가 요요현상을 방지하는 원리는, 약물의 체내에서의 흡수속도는 탕제(물약)>환제(알약)의 순서인데, 탕제를 급작스럽게 중단하였을 때의 인체의 반응을 보다 작용이 완만한 환제로 대체하여 약에 대한 의존성을 서서히 없애는 것입니다.In the present invention, the principle of preventing the yo-yo phenomenon is that the rate of absorption of the drug in the body is in the order of decoction (pill)> pill (pill). Is replaced with a more gentle pill to slowly eliminate the dependency on the drug.
본 발명에 있어서, 마황(Ephedrae herba)은 지방산화작용이 강하며 기존 식사량보다 적은 양으로도 포만감을 느끼게 함으로써 식욕억제작용을 한다. 마황은 마황과의 떨기나무 초마황(Ephedra sinica Stapf.)의 줄기를 가리킨다. 때로는 목적마황(Ephedra equisetina BUNGE)의 줄기를 가리키는 경우도 있다. 마황은 알칼로이드를 1 내지 2% 함유하고 있으며, 그 중에서 에페드린이 40 내지 90%를 차지한다. 에페드린은 지방산화작용이 강하므로 이를 통해 체중을 감소시키는 역할을 한다. 에페드린은 l-에페드린, d-수도에페드린, d-노르수도에페드린, l-메틸에페드린의 순서로 존재한다. 에페드린은 이뇨 작용이 있으며, 체중 감소 작용이 있지만, 혈관 수축 작용 또한 있어서 혈압을 상승시키고 중추 신경계를 흥분시키는 부작용도 갖고 있다. 따라서, 이러한 부작용을 없애면서도 체중 감소 효과를 유지할 수 있는 최적 농도 범위를 결정하여야 한다. 본 발명자들은 1일 섭취하는 에페드린의 양이 0.22 내지 0.44mg인 경우에는 체중 감소의 효과를 나타내면서도 상기와 같은 부작용이 없는 우수한 효과를 나타낼 수 있다는 것을 밝혔다. 1일 섭취량이 0.22mg 미만인 경우에는 체중 감소 효과가 미미하며, 0.44mg을 초과하는 경우에는 상기와 같은 부작용을 나타낼 위험이 있다. 이와 같은 최적의 에페드린 함량 범위는 1일 섭취 마황의 농도가 2.33g 내지 4.67g 범위내에 속하는 경우에 달성될 수 있다.In the present invention, Ephedrae herba has a strong fatty acid action and suppresses appetite by making you feel full even with a smaller amount than a conventional meal. Ephedra refers to the stem of Ephedra sinica Stapf. Sometimes it also refers to the stem of Ephedra equisetina BUNGE. Ephedra contains 1-2% of alkaloids, of which ephedrine accounts for 40-90%. Ephedrine has a strong fatty acid action, thereby reducing weight. Ephedrine is present in the order of l-ephedrine, d- pseudoephedrine, d-norsudoephedrine, l-methylephedrine. Ephedrine has a diuretic effect, weight loss action, but also vasoconstrictive action has an adverse effect of raising blood pressure and exciting the central nervous system. Therefore, it is necessary to determine the optimal concentration range that can maintain the weight loss effect while eliminating these side effects. The present inventors found that when the amount of ephedrine ingested per day is 0.22 to 0.44 mg, the weight loss effect may be excellent but the above side effects may not be exhibited. If the daily intake is less than 0.22mg weight loss effect is insignificant, if it exceeds 0.44mg there is a risk of such side effects. Such an optimal ephedrine content range can be achieved when the concentration of ephedra per day is in the range of 2.33 g to 4.67 g.
상엽(Mori folium)은 본 발명에 따른 조성물에 있어서 항산화작용을 나타내는 요소이다. 상엽은 모루스속(Morus)속 뽕나무의 잎을 가리킨다. 특히, 갈잎큰키나무 뽕나무(Morus alba LINNE), 산뽕나무(Morus bombycis KOIDZ), 가새뽕(Morus bombycis KOIDZ for. dissecta NAKAI)의 잎을 가리킨다. 상엽은 발열, 두통, 안구충혈을 제거하고, 폐열로 해수가 있을 때 이용되며, 구갈이 있을 때에 차로 달여서 마신다. 또한 피부의 두드러기를 가라앉힌다. 상엽에는 루틴(rutin), 퀘르세틴(quercetin), 이소퀘르시트린(isoquercitrin), 모라세틴(moracetin), 퀘르세틴-3-트리글루코시드(quercetin-3-triglucoside), 이노코스테론(inokosterone), 엑디스테론(ecdysterone) 등이 함유되어 있다. 그 중에서 특히, 루틴을 다량 함유하고 있는데, 이는 플라보노이드의 한 종으로서 인체에서 합성되지 않는 비타민C의 흡수를 촉진하여 노화를 억제하는 효능이 있다. 루틴은 2-페닐-3,5,7,3',4'-펜타하이드록시 벤조피론이다. 이를 통해 살이 빠짐에 따라 생길 수 있는 피부 주름을 예방할 수 있다. 또한 무리한 다이어트가 되지 않도록 조절하는 작용도 있으며, 체중 감소 효능도 있다.Morion folium is an element that exhibits antioxidant activity in the composition according to the present invention. The upper leaves refer to the leaves of the Morus genus mulberry. In particular, it refers to the leaves of the leaves of Morus alba LINNE, Morus bombycis KOIDZ, Morus bombycis KOIDZ for. Dissecta NAKAI. The upper lobe is used to remove fever, headaches, and eye redness, and when the sea water is used as lung fever. It also reduces the hives of the skin. The upper lobe contains rutin, quercetin, isoquercitrin, moracetin, quercetin-3-triglucoside, inosterone and exosterone (ecdysterone) and the like. In particular, it contains a large amount of rutin, which is a species of flavonoids has the effect of inhibiting aging by promoting the absorption of vitamin C that is not synthesized in the human body. The routine is 2-phenyl-3,5,7,3 ', 4'-pentahydroxy benzopyrone. This will help prevent wrinkles on your skin as you lose weight. In addition, there is a function to control the diet is not excessive, weight loss is also effective.
창출(Atractylodis rhizoma)은 본 발명에 따른 조성물에서 소화기능을 증진하여 식사 후 인체에 필요한 성분은 흡수하고 노폐물은 신속하게 대소변으로 배설케 하는 기능을 한다. 창출은 국화과의 여러해살이풀 삽주(Atractylodes japonica KOIDZ)의 뿌리줄기이다. 창출은 소화 기관에 정체된 습을 제거하고 건위 작용을 나타내므로 배가 더부룩하거나 메스껍고, 구토, 묽은 변이 있는 증상 및 사지가 나른하며 설태가 두껍게 끼는 증상에 탁월한 반응을 보인다. 특히, 여름철 설사, 소아 복통설사, 음식감소, 위산과다, 위, 십이지장 궤양 등의 증상에 광범위하게 활용된다. 창출은 정유가 5 내지 9% 함유되어 있으며, 이 중 주성분은 세스퀴테르펜(sesquiterpene)의 히네솔(hinesol)로 정유 성분 중 약 55.7중량%를 차지한다. 그 외에, 아트락티론(atractylon), 악트락티롤(actractylol), 비타민 A, B, β-유데스몰(eudesmol), 엘레몰(elemol) 등을 함유한다.Creation (Atractylodis rhizoma) is to enhance the digestive function in the composition according to the invention to absorb the components necessary for the human body after meals and to function as a waste to excrete quickly urine. Creation is the root stem of the Atractylodes japonica KOIDZ of the Asteraceae. Creation removes moisture that has stagnated in the digestive tract and exhibits a sensational action, making it an excellent response to swelling or nausea, vomiting, thin stools, and drowsiness and thick tongues. In particular, it is widely used for symptoms such as summer diarrhea, childhood abdominal diarrhea, reduced food, excessive stomach acid, stomach, duodenal ulcer. Generating contains 5 to 9% of essential oils, the main component of which is hesinsol of sesquiterpene, which accounts for about 55.7% by weight of essential oils. In addition, it contains atractylon, atractylol, vitamins A, B, β-eudesmol, elemol and the like.
택사(Alismatis rhizoma)는 본 발명에 따른 조성물에서 상기 창출을 도와 소화기능을 증진하는 역할을 한다. 택사는 택사과의 여러해살이풀 택사(Alisma canaliculatum A. BR. et BOUCHE), 질경이택사(Alisma plantago-aquatica LINNE var. orientale SAMUELS.)의 덩이뿌리이다. 택사는 많은 종류의 트리테르페노이드 화합물을 함유한다. 특히 알리솔 A.B, 알리솔 A 모노아세테이트, 에피알솔 A 등의 성분을 함유한다.Taxi (Alismatis rhizoma) serves to help the creation in the composition according to the invention to promote digestion. Taxi is a tuber of Alisma canaliculatum A. BR. Et BOUCHE, Alisma plantago-aquatica LINNE var. Orientale SAMUELS. Taxa contains many kinds of triterpenoid compounds. In particular, it contains components such as alisol AB, alisol A monoacetate, epialsol A and the like.
산사(Crataegii fructus)는 본 발명에 따른 조성물에서 상기 창출과 함께 소화기능을 증진시키는 역할을 한다. 산사는 장미과의 갈잎큰키나무 산사나무(아가위나무)(Crataegus pinnatifida BUNGE), 좁은산사나무(Crataegus pinnatifida BUNGE var. psilosa C. K. SCHNEID.), 넓은잎산사나무(Crataegus pinnatifida BUNGE var. major N.E.BR.)의 열매이다. 산사는 건위 작용 및 소화 증진 작용이 있어서, 소화불량, 육식 소화 장애, 복통 등에 탁월한 반응을 보인다. 따라서, 비만 치료에 있어 소화의 문제를 해결할 수 있다. 또한, 콜레스테롤의 흡수를 방지하고 지방산 및 동물 지방 식품의 소화 증진에 현저한 효과가 있다. 따라서, 비만 치료에 효과가 있다. 산사에는 플라보노이드 화합물, 유기산, 당류, 비타민C가 함유되어 있다. 특히, 하이퍼오시드(hyperoside), 퀘르세틴, 안토시아니딘, 올레아놀산, 타르타르산, 시트르산, 크라세골산(crategolic acid), 어솔산(ursolic acid) 등의 플라보노이드 화합물을 함유한다.Sansa (Crataegii fructus) serves to enhance the digestive function with the creation in the composition according to the invention. The hawthorn is the fruit of the Rosaceae Larch hawthorn ( crataegus pinnatifida BUNGE), the narrow hawthorn ( Crataegus pinnatifida BUNGE var. Psilosa CK SCHNEID.), And the broad-leaved hawthorn ( Crataegus pinnatifida BUNGE var. Major NEBR.) to be. Sansa has a healthy and digestive action, and excellent response to indigestion, carnivorous digestive disorders, abdominal pain. Therefore, it is possible to solve the problem of digestion in the treatment of obesity. In addition, there is a significant effect in preventing the absorption of cholesterol and enhancing the digestion of fatty and animal fat foods. Therefore, it is effective in treating obesity. Sansa contains flavonoid compounds, organic acids, sugars, and vitamin C. In particular, it contains flavonoid compounds, such as hyperoside, quercetin, anthocyanidin, oleanolic acid, tartaric acid, citric acid, cratesgolic acid, and ursolic acid.
괴화(Sophorae flos)는 본 발명에 따른 조성물에서 상기 상엽과 함께 항산화작용을 한다. 괴화는 콩과의 갈잎큰키나무 회화나무(Sophora japonica LINNE)의 꽃봉오리이다. 괴화는 간과 동맥 및 혈중 콜레스테롤치를 내리는 작용을 하며, 완만한 사하작용을 나타낸다. 괴화 역시 루틴을 다량 함유하고 있다. 특히 꽃술에 무려 28%나 함유되어 있으며 꽃이 핀 후에는 10% 정도 함유되어 있다. 따라서 꽃이 피기 전에 사용하는 것이 바람직하다. 루틴은 인체에서 합성되지 않는 비타민C의 흡수를 촉진하여 노화를 억제하는 효능이 있다. 이를 통해 살이 빠짐에 따라 생길 수 있는 피부 주름을 예방할 수 있다. 또한 괴화는 무리한 다이어트가 되지 않도록 조절하는 작용도 있으며, 체중 감소 효능도 있다. 괴화는 0.4% 트리테르펜계 사포닌을 포함하고 있으며, 가수분해에 의해서 베툴린, 소포라디올과 포도당, 글루쿠론산을 얻을 수 있다. 또한 꽃봉오리에서는 소포린A 14%, 소포린B 1.25%, 소포린C 0.35%를 얻을 수 있다. 소포린A는 루틴과는 다른 플라보노이드이고, B, C 는 스테롤이다. 또한 탄닌질이 함유되어 있고, 생화에는 0.66%가 함유되어 있다.Sophorae flos has antioxidant activity with the upper lobe in the composition according to the present invention. Honeysuckle is a bud of Sophora japonica LINNE. Necrosis acts to lower the liver, arteries, and blood cholesterol levels, and has a mild lowering action. Aggregation also contains large amounts of rutin. In particular, flower sake contains 28%, and after flowering, it contains about 10%. Therefore, it is desirable to use before flowering. Rutin has the effect of inhibiting aging by promoting the absorption of vitamin C that is not synthesized in the human body. This will help prevent wrinkles on your skin as you lose weight. In addition, the weight of the diet is not an excessive diet, and the effect of weight loss. Aggregation contains 0.4% triterpene-based saponins, and hydrolysis can yield betulin, sophoradiol, glucose, and glucuronic acid. In buds, Sophorin A 14%, Sophorin B 1.25%, and Sophorin C 0.35% can be obtained. Sophorin A is a flavonoid different from rutin, and B and C are sterols. It also contains tannins, and 0.66% of the fresh flowers.
단삼(Salviae miltiorrhizae radix)은 본 발명에 의한 조성물에서 항산화작용을 하는 물질이며, 마황의 부작용 또한 억제하는 작용을 한다. 단삼에는 다량의 탄시논이라는 성분이 존재하는데, 이것이 항산화작용이 강하다. 단삼은 마음을 편안하게 하므로 가슴이 답답하고 잠이 오지 않는 불면증 및 심계항진 등에 효과가 있다. 단삼은 관상 동맥 확장 작용이 있어서 혈류량을 현저히 증가시키고 지질 대사를 활성화시켜 콜레스테롤을 강화시킨다. 단삼은 꿀풀과의 여러해살이풀 단삼(Saliva miltiorrhiza BUNGE)의 뿌리이다. 단삼에는 탄시논I, 탄시논 IIA, 탄시논 IIB, 크립토탄시논, 이소탄시논 등이 함유되어 있다.Salviae (Salviae miltiorrhizae radix) is an antioxidative substance in the composition according to the present invention, and also serves to suppress the side effects of ephedra. Dansam contains a large amount of tanshinone, which has strong antioxidant activity. Dansam soothes the heart, so it is effective for insomnia and palpitations that are hard to sleep and sleepless. Salvia has coronary artery dilation, which significantly increases blood flow and activates lipid metabolism to strengthen cholesterol. Salvia is the root of Saliva miltiorrhiza BUNGE. Dansamon contains tanshinone I, tanshinone IIA, tanshinone IIB, kryptontansinone and isotansinone.
결명자(Cassiae semen)는 본 발명에 의한 조성물에서 상기 창출 또는 산사와 함께 소화기능을 촉진하는 역할을 한다. 그 중에서도, 이뇨 작용과 대변을 잘 보게 하는 작용이 있으며, 특히 변을 묽게 하는 사하작용을 하여 숙변 제거에 큰 효과가 있으므로 건강에도 큰 도움이 되며 체중 조절에도 한 역할을 한다. 또한, 콜레스테롤 강하로 죽상 동맥경화 형성에 억제 작용을 나타낸다. 결명자는 콩과의 한해살이풀인 결명자(Casssia tora LINNE)의 종자이다. 결명자는 크리소파놀, 에모딘, 알로에-에모딘, 레인, 파이사이언(physcion), 오부수틴 등의 성분을 함유하고 있다.Cassiae semen plays a role in promoting the digestive function with the production or hawthorn in the composition according to the present invention. Among them, there is a diuretic effect and the action to see the stool well, in particular, the action of dilute stool thinning has a great effect on the removal of stool, so it is very helpful for health and also plays a role in weight control. In addition, cholesterol lowering has an inhibitory effect on the formation of atherosclerosis. Cassia is the seed of the Casssia tora LINNE, a legume annual. The deficiency contains components such as chrysopanol, emodin, aloe-emodin, lanes, physcion, obusutin and the like.
감초(Glycyrrhizae radix)는 본 발명에 따른 조성물에서 다른 약재들을 조화시켜 주고 인체에 대한 해독작용을 나타내는 역할을 한다. 감초는 콩과의 여러해살이풀 감초(Glycyrrhiza uralensis FISCH.), 창과감초(Glycyrrhiza inflata BAT.)의 뿌리이다. 감초는 여러 약물 중독에 대한 해독 작용을 한다. 또한 심장 율동이 일정하지 않아 가슴 속이 답답하고 편안치 않아서 팔다리를 가만히 두지 못하는 증상과 불면증이 있고 추웠다 더웠다 하는 증상을 치료하는 효과가 있다. 따라서 감초는 해독 작용뿐만이 아니라 마황의 부작용을 억제하는 효과까지 있다. 감초는 트리테르펜계 사포닌, 글리시리진(glycyrrhizin)이 다량(6 내지 14%) 함유되어 있다. 또한, 글리시리즈산(glycyrrhizic acid), 글리시레틴산(glycyrrhetinic acid), 리퀴리틴, 이소리퀴리틴, 리퀴리티제닌, 이소리퀴리티제닌 등을 함유하고 있다.Licorice (Glycyrrhizae radix) serves to harmonize other medicines in the composition according to the present invention and exhibit detoxification to the human body. Licorice is the root of the legume perennial licorice ( Glycyrrhiza uralensis FISCH.) And Glycyrrhiza inflata BAT. Licorice has a detoxifying effect on many drug addictions. In addition, the heart rhythm is not constant because the heart is stuffy and uncomfortable, so that the limbs can not stand still and insomnia and cold, it is effective to treat the symptoms. Therefore, licorice has the effect of suppressing side effects of ephedra as well as detoxification. Licorice contains a large amount (6 to 14%) of triterpene saponins and glycyrrhizin. It also contains glycyrrhizic acid, glycyrrhetinic acid, liqueurin, insoriquiritin, liquiritigenin, insoriquirigeninine and the like.
구기자(Lycii fructus)는 본 발명에 의한 조성물에 있어서 상기 다른 약재와 함께 항산화 작용을 한다. 구기자에는 루틴이 다량 함유되어 있는데 상기 언급한 바와 같이 루틴은 항산화 물질로서 인체에서 합성되지 않는 비타민C의 흡수를 촉진하여 노화를 억제하는 효과가 있다. 구기자는 구기자나무(Lycium chinense MILL.), 영하구기자(Lycium barbatum LINNE)의 성숙한 열매이다. 구기자에는 글리신 등의 다당체와 베타인, 파이사린(physarin), 여러 종류의 아미노산, 비타민 B1, B2, C 등이 함유되어 있다. 한편, 구기자는 콜레스테롤치의 강하 작용과 항지방간 작용도 있다. 이를 통해 체중 감소의 효과도 가져올 수 있다.Wolfberry (Lycii fructus) has an antioxidant action with the other medicine in the composition according to the present invention. Gojija contains a large amount of rutin. As mentioned above, rutin is an antioxidant that promotes the absorption of vitamin C, which is not synthesized in the human body, and has the effect of inhibiting aging. Wolfberry is a mature fruit of Lycium chinense MILL. And Lycium barbatum LINNE. Wolfberry contains polysaccharides such as glycine, betaine, physarin, various amino acids, vitamins B1, B2, and C. On the other hand, goji berries have a cholesterol-lowering action and anti-fatty action. This can also have the effect of weight loss.
오미자(Schizandrae fructus)는 본 발명에 따른 조성물에 있어서, 한약 제재의 쓴맛을 완화시키는 역할을 하며, 마황의 지나친 식욕 억제를 견제하는 역할을 한다. 오미자는 목련과의 낙엽 덩굴나무 오미자(Schizandra chinensis BAILL.), 흑오미자(Schizandra nigra MAXIM.)의 성숙한 열매이다. 남오미자(Kadsura japonica (THUNB.) DUNAL)의 열매도 사용한다. 오미자는 수렴작용이 있어서 피부의 땀샘을 수축시켜 땀이 많아지는 것을 방지하며, 음혈 부족으로 가슴이 뛰고 잠을 이루지 못하면서 꿈이 많은 증상을 완화시킬 수 있다. 따라서 오미자는 마황의 부작용을 억제하는 효과가 있다. 과실에는 정유가 약 3% 함유되어 있으며, 그 정유 속에는 다량의 세스쿠카렌, β-2-비스아볼렌, β-카미그렌, α-일란진 등이 함유되어 있다. 그 외에도 시트르산 12%, 말산 10%, 타르타르산, 스키잔드린, 데옥시스키잔드린, γ-스키잔드린, 수도-γ-스키잔드린, 스키잔드롤 등을 함유하고 있다.Schizandrae fructus (Schizandrae fructus), in the composition according to the present invention, serves to alleviate the bitter taste of herbal medicines, and serves to prevent excessive appetite suppression of ephedra. Schizandra chinensis BAILL. And Schizandra nigra MAXIM. Are the mature fruits of Magnoliaceae. It also uses the fruit of Kadura japonica (THUNB.) DUNAL. Schisandra has a convergent action to shrink the glands of the skin to prevent sweating, and because of lack of bleeding, the heart beats and fails to sleep, which can alleviate many dreamy symptoms. Therefore, Schisandra chinensis has the effect of suppressing the side effects of ephedra. The fruit contains about 3% of essential oils, and the essential oils contain large amounts of sesuccarene, β-2-bisabolene, β-camiglen, and α-ylazine. In addition, it contains 12% citric acid, 10% malic acid, tartaric acid, skidzandrin, deoxysukidrin, γ-skidrindrin, water-γ-skidrindrin, and skidrol.
본 발명에 의한 조성물은 의약 조성물일 수도 있고, 식품 조성물일 수도 있다. 의약 조성물인 경우, 경구 투여하며, 투여량은 일일 에페드린 투여량이 성인 기준으로 0.22 내지 0.44mg이다. 제제화는 건조 생약 혼합물의 형태로도 가능하며, 상기 건조 생약 혼합물을 추출용매에 넣고 추출한 용액 조성물의 형태로도 가능하다. 또한, 약제학적 조성물로 제제화할 경우, 유효 성분에 악영향을 미치지 않는 한, 필요에 따라 의약에 사용되는 각종 보조제, 예컨대 담체나 기타 첨가제, 예컨대 안정제, 완화제, 유화제 등을 첨가할 수 있다. 제형으로는, 정제, 환제, 캅셀제, 과립제, 산제, 엑스제, 전제, 침제 등을 비롯하여 생약성분의 약제학적 제제에 적합한 어떠한 제형으로도 할 수 있다. The composition according to the present invention may be a pharmaceutical composition or may be a food composition. In the case of pharmaceutical compositions, it is administered orally and the dosage is from 0.22 to 0.44 mg per day for adult ephedrine. Formulation may also be in the form of a dry herbal mixture, or may be in the form of a solution composition in which the dry herbal mixture is placed in an extraction solvent and extracted. In addition, when formulated into a pharmaceutical composition, various auxiliaries used in medicine, such as carriers or other additives such as stabilizers, emollients, emulsifiers and the like, may be added as necessary, so long as they do not adversely affect the active ingredient. The formulation may be any formulation suitable for pharmaceutical preparations of herbal ingredients, including tablets, pills, capsules, granules, powders, extracts, premises, acupuncture and the like.
이하, 본 발명의 바람직한 일실시예를 들어 본 발명을 더욱 상세히 설명하고자 하나, 이는 예시적 목적에 불과할 뿐 본 발명의 권리범위를 한정하고자 하는 것은 아니다. Hereinafter, the present invention will be described in more detail with reference to a preferred embodiment of the present invention, which is for illustrative purposes only and is not intended to limit the scope of the present invention.
<실시예 1: 생약 건조 혼합물의 제조>Example 1 Preparation of Herbal Dry Mixture
창출 12g, 산사, 택사, 구기자 각 8g, 괴화, 상엽, 결명자, 단삼 각 6g, 마황 4g, 오미자, 감초 각 3g을 혼합함으로써 본 발명에 의한 체중 감소용 생약 건조 혼합물을 제조하였다. The herbal dry mixture for weight loss according to the present invention was prepared by mixing 12 g of production, 8 g of hawthorn, taxa, 8 g each of Goji, chrysanthemum, upper lobe, C. deciduous, 6 g of Salvia ginseng, 4 g of Ephedra, and 3 g of Schisandra chinensis.
<실시예 2: 액상 조성물의 제조>Example 2: Preparation of Liquid Composition
상기 실시예1에서 제조된 생약 건조 혼합물을 1첩 분량으로 하여 총 20첩(1제에 해당)의 양 만큼의 생약 건조 혼합물 1400g을 5리터의 물에 넣고 1.5기압에서 115 내지 120℃로 2시간 가열하여 얻은 수용액상의 추출물을 48개의 팩에 110ml씩 담았다. 이렇게 하여 제조된 약제는 하루 2팩씩 아침, 저녁으로 식후 30분에 24일간 복용한다. 1400 g of the dry powder mixture of the total amount of 20 tablets (corresponding to the first agent) was added to the volume of the crude drug dry mixture prepared in Example 1, in 5 liters of water for 2 hours at 115 to 120 ° C. 110 ml of the aqueous solution obtained by heating was contained in 48 packs. The medicines thus prepared are taken two packs a day, morning and evening, for 24 minutes at 30 minutes after meals.
<실시예 3: 체중 감소용 키트의 제조1>Example 3 Preparation of Weight Loss Kit 1
상기 실시예1에 따른 생약 건조 혼합물을 1첩 분량으로 하고 총 20첩으로 이루어진 체중 감소용 생약 조성물을 하기와 같이 하여 제조된 요요현상 방지용 환제와 함께 포함하는 체중 감소용 키트를 제조하였다. To prepare a weight loss kit comprising a herbal composition for dry weight according to Example 1 in a dose and a weight loss herbal composition consisting of a total of 20 laps together with a pill for preventing the yo-yo phenomenon prepared as follows.
창출 120g, 산사, 택사 구기자 각각 80g, 괴화, 상엽, 결명자, 단삼 각각 60g, 오미자, 감초 각 30g을 잘게 빻아 분말을 만들었다. 그 분말에 꿀 600g을 넣고 반죽하여 녹두 크기(직경 0.5cm)의 환으로 만들어 음지에서 건조시켰다. 이렇게 제조된 환은 상기 키트에 일일 3회 식후 30분에 40 내지 50알씩 복용할 수 있도록 하는 양으로 포함시켰다. Powder 120g, hawthorn, talcum wolfberry, 80g each, lumps, leaves, gyeoljaja, 60 g each, red ginseng, Schisandra chinensis, 30 g each licorice. 600 g of honey was added to the powder and kneaded to make a ring of mung bean size (0.5 cm in diameter) and dried in the shade. Thus prepared ring was included in the kit in an amount to be taken 40 to 50 tablets 30 minutes after eating three times a day.
상기 키트는 먼저 상기 체중 감소용 생약 조성물을 모두 복용한 후 상기 요요현상 방지용 환제를 복용하도록 하는 안내서를 포함하도록 구성되었다.The kit is configured to include a guide to first take all of the herbal composition for weight loss and then take the anti-yo-yo pill.
<실시예 4: 체중 감소용 키트의 제조2>Example 4 Preparation of Weight Loss Kit 2
상기 실시예2에 따른 액상 조성물 48팩을 상기 실시예3과 같이 하여 제조된 요요현상 방지용 환제와 함께 구성하여 본 발명에 의한 체중 감소용 키트를 구성하였다. 이 키트 역시 먼저 상기 체중 감소용 액상 조성물을 모두 복용한 후에 상기 요요현상 방지용 환제를 복용하도록 지시하는 안내서를 포함하도록 구성되었다. 48 packs of the liquid composition according to Example 2 were composed together with the pill for preventing the yo-yo phenomenon prepared in the same manner as in Example 3 to construct a weight loss kit according to the present invention. The kit is also configured to include a guide for instructing to take the anti-yo-yo pill after first taking all of the weight loss liquid composition.
<실험예 1: 체중 감량 효과의 임상 실험>Experimental Example 1: Clinical Trial of Weight Loss Effect
상기 실시예 2에 따른 체중 감소용 조성물을 다양한 연령을 갖는 남자 3명, 여자 9명으로 구성된 피험자들에게 24일간 투여하여 다음과 같은 결과를 얻었다. 하기 피험자들은 상기 조성물을 복용하는 것 이외에는 평상시와 다른 점이 없었다. 즉, 평소보다 음식 섭취량을 줄인다거나 평소에 하지 않던 운동을 추가로 하지는 않았다.The weight loss composition according to Example 2 was administered to subjects consisting of three males and nine females having various ages for 24 days to obtain the following results. The following subjects were not different from usual except taking the composition. In other words, they did not reduce their food intake more than usual or did not add exercise that they did not normally do.
상기 표에 나타난 바와 같이, 대부분의 피험자들에게서 감량 효과가 있는 것을 알 수 있었다. As shown in the table, it was found that the weight loss effect in most subjects.
<실험예 2: 요요현상 시험>Experimental Example 2: Yo-Yo Phenomenon Test
상기 실험예1에 따라 24일간 실시예2에 따른 조성물을 복용한 후 1달간 상기 실험예1에서의 피험자들 중 상기 8 내지 10번을 제외한 피험자들에게 상기 실시예3에 따른 요요현상 방지용 환제를 일일 3회 식후 30분에 40-50알씩 복용시킨 결과 9명 모두에게서 요요현상이 발생하지 않았음을 확인하였다. 즉, 상기 24일간에 걸쳐 감량된 체중이 그대로 1달간 유지되는 것을 알 수 있었다. After taking the composition according to Example 2 for 24 days according to Experimental Example 1 to the subjects except for the 8 to 10 of the subjects in Experimental Example 1 for 1 month to the yoyo phenomenon prevention pills according to Example 3 As a result of taking 40-50 tablets at 30 minutes after eating 3 times a day, it was confirmed that no yoyo phenomenon occurred in all 9 patients. That is, it was found that the weight lost over the 24 days is maintained for 1 month.
<실험예 3: 에페드린의 부작용 테스트>Experimental Example 3: Side Effects Test of Ephedrine
상기 실시예2의 조성물은 일일 에페드린의 투여량이 0.316mg이다. 실시예2에서 사용된 마황은 총 4g x 20 = 80g이며, 이를 24일간 투여하므로 하루에는 3.33g의 마황이 투여된다. 그런데, 상기 실시예2의 추출방법에 따라 제조된 마황 100g의 수용액 상의 추출물에는 에페드린의 함량은 대략 9.49mg 정도이기 때문에, 1일 섭취되는 에페드린의 투여량은 0.316mg이 되는 것이다. 상기 언급한 바와 같이, 본 발명에서 바람직한 에페드린의 1일 투여량은 성인 기준 0.22 내지 0.44mg/일이다. 0.22mg/일 미만인 경우에는 충분한 체중 감량 효과를 달성하기가 어렵고, 0.44mg/일을 초과하는 경우에는 신경 및 심장 활동의 활성화로 인한 심장마비나 발작과 조울증, 망상, 불면증, 가슴 두근거림, 두통 등의 부작용이 초래될 수 있다. In the composition of Example 2, the daily dose of ephedrine is 0.316 mg. Ephedra used in Example 2 is a total of 4g x 20 = 80g, it is administered for 24 days, so 3.33g of ephedra is administered per day. However, since the content of ephedrine is about 9.49 mg in the extract of the ephedra 100g aqueous solution prepared according to the extraction method of Example 2, the dose of ephedrine consumed per day is 0.316 mg. As mentioned above, the preferred daily dose of ephedrine in the present invention is 0.22 to 0.44 mg / day on an adult basis. Below 0.22 mg / day it is difficult to achieve a sufficient weight loss effect, and above 0.44 mg / day heart attack or seizures and bipolar disorder, delusion, insomnia, palpitations, headaches caused by activation of nerve and heart activity And other side effects may result.
이에 대해, 일일 에페드린 투여량이 0.1mg, 0.2mg, 0.22mg, 0.316mg, 0.44mg, 0.5mg, 1.0mg, 10mg인 경우 각각의 평균동맥압(MBP)과 심박수(HR)를 측정하였다. 건강한 성인남녀 10명에게 상기 투여량의 에페드린을 투여시키고 1분이 경과된 시점에서 평균동맥압(mmHg)과 심박수를 측정(78354C Hewlett Packard, USA)하여 투여전에 대한 증가율(%)을 평균낸 결과는 다음과 같다. In contrast, the average arterial pressure (MBP) and heart rate (HR) were measured when the daily dose of ephedrine was 0.1 mg, 0.2 mg, 0.22 mg, 0.316 mg, 0.44 mg, 0.5 mg, 1.0 mg, 10 mg. The average arterial pressure (mmHg) and heart rate were measured (78354C Hewlett Packard, USA) at 10 minutes after the dose of ephedrine was administered to 10 healthy adult men and women. Same as
상기 결과로부터, 에페드린 일일 투여량이 0.44mg을 초과하는 경우, 구체적으로 0.5mg 이상이 되는 시점부터는 평균동맥압 및 심박수 모두 증가하기 시작하는 것을 알 수 있었다. 따라서, 일일 에페드린 투여량은 0.44mg까지의 범위가 안전한 것이 입증되었다. From the above results, it can be seen that when the daily dose of ephedrine exceeds 0.44 mg, specifically the mean arterial pressure and heart rate start to increase from 0.5 mg or more. Therefore, the daily ephedrine dosages in the range up to 0.44 mg proved safe.
또한, 건강한 성인남녀 10명에 대해 실시예2와 같이 하여 조성물을 제조하되, 마황의 일일 투여량의 범위를 달리한 수개의 조성물을 제조하였다. 조성물은 마황의 일일 투여량이 1g, 2g, 2.33g(에페드린 함량 0.22mg), 3.33g(에페드린 함량 0.316mg, 실시예2), 4.67g(에페드린 함량 0.44mg), 4.7g 및 5g이 되도록 하였다. 상기와 같이 제조된 각 조성물을 조성물 당 24일간 각 피험자들에게 전체 120일간 투여한 후 체중의 변화(감소율)를 측정하였다. 그 후 10명의 체중 감소율은 평균내었다. 그 결과는 다음과 같다. In addition, the composition was prepared in the same manner as in Example 2 for 10 healthy adult men and women, but several compositions were prepared in which the daily dosage of ephedra was varied. The composition was such that the daily doses of ephedra were 1 g, 2 g, 2.33 g (0.22 mg of ephedrine), 3.33 g (0.316 mg of ephedrine, Example 2), 4.67 g (0.44 mg of ephedrine), 4.7 g and 5 g. Each composition prepared as described above was administered to each subject for 24 days per composition for a total of 120 days, and then the change in body weight (reduction rate) was measured. Since then, the weight loss rate of 10 people has averaged. the results are as follow.
상기 결과로부터 알 수 있듯이, 마황의 일일 투여 농도가 2g인 경우(에페드린 일일 투여량이 0.22mg 미만인 경우)에는 체중 감소 효과가 미미하나, 2.33g(에페드린 일일 투여량이 0.22mg)부터는 우수한 체중 감소 효과를 나타낸다. 따라서, 최소한의 체중 감량 효과를 내기 위해서는 마황의 일일 투여 농도가 2.33g 이상이어야 한다. 즉, 에페드린의 일일 투여량은 0.22mg 이상이어야 한다. As can be seen from the above results, when the daily dose of ephedra is 2g (ephedrine daily dose less than 0.22mg), the weight loss effect is minimal, but from 2.33g (ephedrine daily dose 0.22mg) shows an excellent weight loss effect . Therefore, in order to have a minimal weight loss effect, the daily dose of ephedra must be at least 2.33 g. In other words, the daily dose of ephedrine should be at least 0.22 mg.
<실험예 4 소화기능 테스트>Experimental Example 4 Digestive Function Test
상기 실험예1에 따라 24일간 실시예2의 조성물을 복용시킨 후 소화기능을 측정하였다. 소화기능은 위에서의 소화능력과 배변의 상태를 기준으로 측정하였다. 위에서의 소화능력은 일정량의 음식물이 섭취되었을 때 속쓰림, 소화불량, 가스참의 정도 등의 자각증상에 대해 문진하였다. 한편, 배변의 상태에 대해서는, 배변의 횟수, 변의 묽은 정도, 가스참의 정도, 복통 등에 대한 자각증상에 대해 문진하였다. 그 결과는 하기 표4와 같았다.Digestive function was measured after taking the composition of Example 2 for 24 days according to Experimental Example 1. Digestive function was measured based on the digestive capacity of the stomach and the state of bowel movements. The digestive ability of the stomach was questioned about subjective symptoms such as heartburn, indigestion, and degree of gas extinguishment when a certain amount of food was ingested. On the other hand, the state of defecation was questioned about subjective symptoms such as the frequency of defecation, the degree of diarrhea, the degree of gas trapping, abdominal pain and the like. The results were as shown in Table 4 below.
+++: 매우 효과있음+++: Very effective
++ : 효과있음++: effective
+ : 효과가 없거나 미약+: Ineffective or weak
<실험예 5 노화의 정도 측정>Experimental Example 5 Measurement of Degree of Aging
상기 실험예1에 따라 24일간 실시예2의 조성물을 복용시킨 후 피험자들의 피부 노화의 정도에 대해 측정하였다. 얼굴의 피부 탄력을 측정할 수 있는 큐토미터(Cutometer SEM 474:Skin Elasticity Meter, Courage+Khazaka electronic GmbH. Germany)를 이용하여 피험자들의 얼굴 부위의 탄력을 측정하여 복용 전과 비교하였다. 그 결과는 하기 표 5에 나타내었다. After taking the composition of Example 2 for 24 days according to Experimental Example 1 was measured for the degree of skin aging of the subjects. The skin elasticity of the subjects was measured by using a cutometer SEM 474: Skin Elasticity Meter, Courage + Khazaka electronic GmbH. The results are shown in Table 5 below.
상기 표에서 알 수 있듯이, 피험자 모두에 있어서 체중 감량에도 불구하고 피부 탄력이 오히려 개선된 것을 알 수 있었다. 이는 본 발명에 따른 조성물이 체중 감소로 인한 피부 탄력 저하를 예방하는 수준을 넘어서, 오히려 피부 탄력 개선의 효과까지 있다는 것을 입증하는 것이다. As can be seen from the table, it was found that the skin elasticity was rather improved despite weight loss in all the subjects. This proves that the composition according to the invention goes beyond the level of preventing skin elasticity deterioration due to weight loss, but rather to the effect of improving skin elasticity.
<실험예 6: 동물시험 데이터>Experimental Example 6: Animal Test Data
생후 12주령이고 체중이 380 내지 410g인 수컷 변종인 Sorague-Dawley 래트를 4개의 대조군과 8개의 실험군으로 나누고 상기 실시예2의 조성물을 4주간 아침 저녁으로 2g씩 하루 2회 경구 투여하였다. 체중은 1주 단위로 측정하였다. 래트의 배양 조건은 표준 조건 하에서 사육하였으며 온도가 조절된 사육실 내에서 12시간 밤/낮의 보통 사이클을 유지시켜 주었다. 먼저 대조군에 대한 결과는 다음 표와 같다. 하기 표의 수치는 래트의 체중(g)을 나타낸다. Sorague-Dawley rats, male strains of 12 weeks old and weighing 380-410 g, were divided into four control groups and eight experimental groups, and the composition of Example 2 was administered orally twice a day for 2 weeks each morning for 4 weeks. Body weight was measured in weeks. The culture conditions of the rats were raised under standard conditions and maintained a normal cycle of 12 hours night / day in a temperature controlled feeding room. First, the results for the control group are shown in the following table. The figures in the table below represent the weight in grams of rats.
표에 나타난 바와 같이, 본 발명에 의한 조성물을 투여하지 아니한 대조군의 경우 래트가 성장함에 따라 자연스럽게 체중이 증가함을 알 수 있었다.As shown in the table, in the control group not administered the composition according to the present invention, it was found that the weight naturally increased as the rat grew.
한편, 실험군에 대한 결과는 다음 표와 같다. On the other hand, the results for the experimental group is shown in the following table.
상기 표에 나타난 바와 같이, 성장하는 연령의 래트임에도 불구하고 본 발명에 의한 조성물 투여 결과 체중이 차츰 감소하는 것을 알 수 있었다. 따라서, 본 발명에 의한 체중 감소용 생약 조성물은 체중 감소 효과가 있음을 입증하는 것이다. 상기 표의 결과는 도 1에 그래프로도 나타내었다. As shown in the table, despite the rat of the growing age, it was found that body weight gradually decreased as a result of administering the composition according to the present invention. Therefore, the herbal composition for weight loss according to the present invention is to demonstrate that there is a weight loss effect. The results of the table are also shown graphically in FIG. 1.
본 발명에 의한 체중 감소용 생약 조성물은 특정 농도의 마황을 함유함으로써 에페드린의 투여로 인한 부작용을 예방하면서도 충분한 체중감소효과를 나타내는 조성물을 제공할 수 있다. 이와 같은 체중 조절 효과와 더불어, 동양인 특유의 체질을 고려하여 소화를 증진시켜 주며 숙변을 제거하고 배변을 용이하게 하는 효과가 있다. 또한, 체중 감소에 따른 노화를 방지하여 피부 탄력을 강화시키고 주름을 감소시키는 효과가 있다. The herbal composition for weight loss according to the present invention may provide a composition exhibiting sufficient weight loss effect while preventing side effects due to the administration of ephedrine by containing ephedra at a certain concentration. In addition to the weight control effect, considering the peculiar constitution of Asians, it promotes digestion, removes stool, and facilitates bowel movement. In addition, there is an effect of preventing aging due to weight loss to strengthen skin elasticity and reduce wrinkles.
도 1은 본 발명에 의한 조성물의 체중 감량 효과를 나타내는 동물 시험 데이터이다. 1 is animal test data showing the weight loss effect of the composition according to the present invention.
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2003-0038371A KR100514132B1 (en) | 2003-06-13 | 2003-06-13 | Composition and kit for losing body weight |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2003-0038371A KR100514132B1 (en) | 2003-06-13 | 2003-06-13 | Composition and kit for losing body weight |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040107544A KR20040107544A (en) | 2004-12-21 |
KR100514132B1 true KR100514132B1 (en) | 2005-09-09 |
Family
ID=37381634
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2003-0038371A Expired - Fee Related KR100514132B1 (en) | 2003-06-13 | 2003-06-13 | Composition and kit for losing body weight |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100514132B1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006059270A1 (en) * | 2006-12-13 | 2008-06-19 | Phenion Gmbh & Co. Kg | Use of Styphnolobium |
KR100888068B1 (en) | 2007-04-19 | 2009-03-11 | 학교법인 동의학원 | Obesity Inhibitory Composition |
KR101883553B1 (en) * | 2016-04-12 | 2018-07-31 | 정대진 | Crude drug composition for improvement of constipation and manufacturing method |
WO2019132416A1 (en) * | 2017-12-29 | 2019-07-04 | 주식회사 누베베 | Method for producing herbal medicinal tablet formulation for treating obesity which can be prescribed based on sasang constitutional medicine |
WO2019132417A1 (en) * | 2017-12-29 | 2019-07-04 | 주식회사 누베베 | Herbal medicinal tablet formulation for treating obesity which can be prescribed based on sasang constitutional medicine |
KR102232076B1 (en) * | 2017-12-29 | 2021-03-25 | 주식회사 누베베 | Method for manufacturing a herbal medicine tablet for using a weight loss agent |
-
2003
- 2003-06-13 KR KR10-2003-0038371A patent/KR100514132B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR20040107544A (en) | 2004-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kulkarni et al. | Indian gooseberry (Emblica officinalis): Complete pharmacognosy review | |
CN104958646A (en) | Chinese medicinal preparation for relaxing bowels and preparation method thereof | |
CN104068177A (en) | Health-care life-lengthening natural plant tea | |
CN104524146A (en) | Traditional Chinese medicine composition for prevention and adjuvant treatment of hypertensive, hyperlipidemia and hyperglycemia and application of traditional Chinese medicine composition | |
KR100514132B1 (en) | Composition and kit for losing body weight | |
KR20020012436A (en) | Healthy food composition for preventing and treatmenting constipation | |
TW202330006A (en) | Composition for preventing, improving or alleviating symptoms relating to qi deficiency and/or blood deficiency | |
CN116492428A (en) | A Chinese medicinal composition for preventing and treating cardiovascular and cerebrovascular diseases | |
CN110538308B (en) | Traditional Chinese medicine composition for hair growth and preparation method thereof | |
CN113332390A (en) | Traditional Chinese medicine composition for tonifying liver and kidney and preparation method thereof | |
KR100504124B1 (en) | Mixture for prevention of obesity | |
KR102745502B1 (en) | Herbal pill composition for weight loss containing Coix lachryma-jobi and Lycium barbarum and its preparation method | |
CN104606570A (en) | Consumptive thirst tea substitute drink suitable for diabetes patients and preparation method of consumptive thirst tea substitute drink | |
CN104435969A (en) | Stomach-invigorating and digestion-promoting potus for treating infantile malnutrition and preparation method thereof | |
KR102693949B1 (en) | Herbal pill composition containing Glycyrrhiza uralensis Fisch for promoting defecation and improving cholesterol and method for preparing the same | |
CN113577137B (en) | Traditional Chinese medicine composition for treating acne and preparation method and application thereof | |
CN103933282A (en) | Traditional Chinese medicine preparation for treating diabetes | |
CN108186799A (en) | Ground bone slender acanthopanax dissipates and preparation method | |
CN107951951B (en) | Traditional Chinese medicine composition for removing senile plaques and preparation method thereof | |
CN105233093A (en) | Traditional Chinese medicine tablet for treating gastroptosis | |
CN105213897A (en) | A kind of weight gaining Chinese medicinal tablet | |
CN105596893A (en) | Traditional Chinese medicine composition for treating hyperlipidaemia and preparation method | |
WO2023074459A1 (en) | Composition for preventing, improving or alleviating symptoms relating to phlegm and dampness | |
CN104225185A (en) | Chewing gum with blood sugar reducing function and production method of chewing gum | |
CN117618480A (en) | Application and preparation method of Panax notoginseng stem and leaf extract for promoting blood circulation, removing blood stasis and anti-thrombosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20030613 |
|
PA0201 | Request for examination | ||
N231 | Notification of change of applicant | ||
PN2301 | Change of applicant |
Patent event date: 20030630 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20050428 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20050823 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20050902 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20050901 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
LAPS | Lapse due to unpaid annual fee | ||
PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20090810 |